Lead Product(s) : Luxdegalutamide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
JSB462 + 177Lu Vipivotide Safety and Efficacy In mCRPC
Details : JSB462 (Luxdegalutamide) is a PROTACs drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.
Product Name : JSB462
Product Type : PROTACs
Upfront Cash : Inapplicable
July 02, 2025
Lead Product(s) : Luxdegalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Luxdegalutamide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
JSB462 + Abiraterone Safety and Efficacy In mHSPC Adults
Details : JSB462 (Luxdegalutamide) is a PROTACs drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Prostatic Neoplasms.
Product Name : JSB462
Product Type : PROTACs
Upfront Cash : Inapplicable
May 28, 2025
Lead Product(s) : Luxdegalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Luxdegalutamide,Abiraterone Acetate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $1,160.0 million
Deal Type : Licensing Agreement
Arvinas Partners with Novartis On Global License for PROTAC® ARV-766
Details : Novartis obtains worldwide development & commercialization rights to ARV-766, Arvinas’ 2nd-generation PROTAC androgen receptor degrader for prostate cancer, including its preclinical AR-V7 program.
Product Name : Undisclosed
Product Type : PROTACs
Upfront Cash : $150.0 million
April 11, 2024
Lead Product(s) : Luxdegalutamide,Abiraterone Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $1,160.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Luxdegalutamide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ARV-766 is an investigational orally bioavailable PROTAC® protein degrader designed to degrade all clinically relevant resistance-driving point mutations of the androgen receptor (AR) and which being investigated forLate-line mCRPC.
Product Name : Undisclosed
Product Type : PROTACs
Upfront Cash : Inapplicable
June 08, 2023
Lead Product(s) : Luxdegalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Luxdegalutamide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Details : ARV-766 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : PROTACs
Upfront Cash : Inapplicable
October 05, 2021
Lead Product(s) : Luxdegalutamide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable